Aligos Therapeutics announces award of an $8.5M NIAID contract

Aligos Therapeutics announced that it has been awarded an $8.5 million National Institute of Allergy and Infectious Diseases, NIAID, contract to conduct nonclinical and clinical studies to advance its pan-coronavirus protease inhibitor ALG-097558 into future Phase 2/3 studies. “It is an honor to be awarded this NIAID contract, which is our second NIH-funding received for the development of novel inhibitors of the coronavirus 3CL protease,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics. “Given that ALG-097558 potently inhibits all forms of coronavirus tested to date, we believe that this compound will be important for the ongoing COVID-19 endemic as well as for the treatment of emergent novel coronavirus infections in humans in the future. These non-dilutive external funds will enable Aligos to continue to advance the ALG-097558 program beyond the ongoing Phase 1 study, which is evaluating single and multiple doses in healthy volunteers.”